Tyme Technologies (TYME) Stock Price, News & Analysis

Company Overview

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Key Stats

• Today's Range: $0.29 to $0.32
• 50-Day Range: $0.24 to $0.35
• 52-Week Range: $0.22 to $1.14
• Volume: 2.68 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $53.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TYME Stock Analysis - Frequently Asked Questions

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03.

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tyme Technologies investors own include NIO (NIO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Tonix Pharmaceuticals (TNXP), SCYNEXIS (SCYX) and Palantir Technologies (PLTR).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/23/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TYME
• CUSIP: N/A
• CIK: 1537917
• Web: www.tymeinc.com
• Phone: (212) 461-2315
• Fax: N/A
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,630,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -28.30%
• Return on Assets: -26.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.06
• Quick Ratio: 14.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.47 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 172,207,000
• Free Float: 143,104,000
• Market Cap: $53.50 million
• Optionable: Optionable
• Beta: 0.93